ixazomib
"
Ixazomib Citrate (1201902-80-8)
Ixazomib Citrate (1201902-80-8) Ixazomib citrate is a proteasome inhibitor that prevents cell growth in solid tumours. This anti-cancer agent is specifically used for the treatment of multiple myeloma. Compared with bortezomib, Ixazomib citrate demonstrates superior pharmacokinetics, efficacy, and anticancer activity. Key Features Proteasome inhibitor for cancer treatment Specifically indicated for multiple myeloma Superior pharmacokinetics compared to bortezomib Enhanced
2-(2,5-dichlorobenzamido)acetic acid (667403-46-5)
2-(2,5-dichlorobenzamido)acetic acid (667403-46-5) 2-(2,5-dichlorobenzamido)acetic acid is a chemical compound used in the preparation of Ixazomib, a pharmaceutical intermediate. This compound serves as a key intermediate in pharmaceutical synthesis, specifically for the production of Ixazomib. Product Specifications Product Name: 2-(2,5-dichlorobenzamido)acetic acid CAS No.: 667403-46-5 Assay: 98% End Use: Ixazomib Molecular Formula: C9H7Cl2NO3 Molecular Weight: 248.06 Shelf
(αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate (179324-87-9)
(R)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate (179324-87-9) (R)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate (179324-87-9) is a specialized chemical compound used in the design and preparation of pharmaceutical agents including Ixazomib and Bortezomib. Product Specifications Product Name: (R)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate CAS No.: 179324-87-9 Assay: 98% End Use:
